Rhythm Pharmaceuticals, Inc. (RYTM) stock

RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30265% above fair value

$115.02+5.16 (+4.70%)

Close on Nov 13, 2026Market cap $7.92BP/E –Yield –

Rhythm Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Rhythm Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Rhythm Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RYTM.

Revenue growth53.5% · median 100.6%

Gross margin89.0% · median 82.3%

Operating margin-83.6% · median 28.8%

Net margin-85.6% · median 35.3%

Advertisement
300 × 250

See a number that looks wrong?